Parkside Financial Bank & Trust bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 339 shares of the company's stock, valued at approximately $50,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Signaturefd LLC boosted its holdings in shares of Medpace by 486.7% in the first quarter. Signaturefd LLC now owns 264 shares of the company's stock valued at $43,000 after acquiring an additional 219 shares in the last quarter. Lansing Street Advisors acquired a new stake in shares of Medpace in the first quarter valued at about $44,000. Prospera Financial Services Inc acquired a new stake in shares of Medpace in the first quarter valued at about $47,000. Meeder Asset Management Inc. acquired a new stake in shares of Medpace in the first quarter valued at about $121,000. Finally, Van ECK Associates Corp lifted its stake in shares of Medpace by 15.9% in the first quarter. Van ECK Associates Corp now owns 772 shares of the company's stock valued at $126,000 after purchasing an additional 106 shares during the period. Hedge funds and other institutional investors own 83.97% of the company's stock.
Get Medpace alerts:Medpace Trading Down 6.1 %
Shares of MEDP opened at $145.38 on Friday. The stock has a market cap of $4.51 billion, a P/E ratio of 25.24 and a beta of 1.47. The company has a 50-day moving average of $161.45 and a two-hundred day moving average of $152.75. Medpace Holdings, Inc. has a 12-month low of $126.94 and a 12-month high of $231.00.
Medpace (NASDAQ:MEDP – Get Rating) last announced its earnings results on Monday, July 25th. The company reported $1.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.34 by $0.12. The company had revenue of $351.21 million during the quarter, compared to analysts' expectations of $344.01 million. Medpace had a net margin of 16.27% and a return on equity of 30.56%. The firm's quarterly revenue was up 26.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.06 earnings per share. As a group, analysts forecast that Medpace Holdings, Inc. will post 6.16 EPS for the current fiscal year.Analyst Upgrades and Downgrades
Several analysts recently commented on MEDP shares. StockNews.com cut shares of Medpace from a "buy" rating to a "hold" rating in a research note on Thursday, September 8th. UBS Group started coverage on shares of Medpace in a research note on Wednesday, September 7th. They issued a "sell" rating and a $142.00 price objective for the company.
Insiders Place Their Bets
In other Medpace news, CEO August J. Troendle bought 22,290 shares of the business's stock in a transaction on Thursday, July 14th. The stock was bought at an average price of $144.59 per share, for a total transaction of $3,222,911.10. Following the completion of the transaction, the chief executive officer now owns 5,505,309 shares in the company, valued at approximately $796,012,628.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO August J. Troendle acquired 22,290 shares of the business's stock in a transaction dated Thursday, July 14th. The stock was acquired at an average price of $144.59 per share, with a total value of $3,222,911.10. Following the completion of the transaction, the chief executive officer now directly owns 5,505,309 shares in the company, valued at approximately $796,012,628.31. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Medpace Investors, Llc acquired 57,426 shares of the business's stock in a transaction dated Thursday, September 22nd. The stock was purchased at an average cost of $154.59 per share, with a total value of $8,877,485.34. Following the transaction, the insider now owns 6,483,019 shares of the company's stock, valued at $1,002,209,907.21. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 520,388 shares of company stock worth $81,752,898. Insiders own 20.60% of the company's stock.
About Medpace
(Get Rating)
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Read More
- Get a free copy of the StockNews.com research report on Medpace (MEDP)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.